Treatment of vascular rejection with rituximab in cardiac transplantation

Journal of Heart and Lung Transplantation

Volumn 24, Issue 9, 2005, Pages 1337-1342

  Garrett Jr , H Edward ^a,b   Duvall Seaman, Denise ^a   Helsley, Beth ^a   Groshart, Kenneth ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b PLLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; OKT 3; RITUXIMAB; TACROLIMUS;

ADOLESCENT; ADULT; ANTIBODY PRODUCING CELL; ARTICLE; B LYMPHOCYTE; CARDIAC GRAFT REJECTION; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE BIOPSY; HEART TRANSPLANTATION; HUMAN; IMMUNOFLUORESCENCE TEST; MALE; POSTOPERATIVE COMPLICATION; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; B-LYMPHOCYTES; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; IMMUNOGLOBULIN G; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; STROKE VOLUME;

EID: 24344482112     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2004.09.003     Document Type: Article

References (22)

1. E.H. Hammond, R.L. Yowell, S. Nunoda Vascular (humoral) rejection in heart transplantation pathologic observations and clinical implications J Heart Transplant 8 1989 430 443
2. E.H. Hammond, R.L. Yowell, G.D. Price Vascular rejection and its relationship to allograft coronary artery disease J Heart Lung Transplant 11 suppl 1992 S111 S119
3. S.L. Olsen, L.F. Wagoner, E.H. Hammond Vascular rejection in heart transplantation clinical correlation, treatment options, and future considerations J Heart Lung Transplant 12 suppl 1993 S135 S142
4. J. Jimenez, J.B. Young Case 2 Cardiogenic shock due to acute vascular rejection in a heart transplant recipient J Heart Lung Transplant 19 2000 817 818
5. L.W. Miller, A. Wesp, S.H. Jennison Vascular rejection in heart transplant recipients J Heart Lung Transplant 12 suppl 1993 S147 S152
6. S.C. Jordan, A.W. Quartel, L.S.C. Czer Posttransplant therapy using high-dose human immunoglobulin (intravenous gammaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action Transplantation 66 1998 800 805
7. A.K. Gopal, O.W. Press Clinical applications of anti-CD20 antibodies J Lab Clin Med 134 1999 445 450
8. A.J. Grillo-López, C.A. White, C. Varns Overview of the clinical development of rituximab first monoclonal antibody approved for the treatment of lymphoma Semin Oncol 26 1999 66 73
9. S. Alas, B. Bonavida Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin-10 autocrine/paracrine loop and results in down-regulation of bel-2 and sensitization to cytotoxic drugs Cancer Res 61 2001 5137 5144
10. V. Ratanatharathorn, E. Carson, J.P. Uberti Anti-CD20 chimeric monoclonal antibody treatment of refractory immune-mediated thrombocytopenia in a patient with chronic GVHD Ann Intern Med 133 2000 275 279
11. M.N. Saleh, J. Gutheil, D. Moore A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia Semin Oncol 27 2000 99 103
12. V. Ganne, N. Siddiqi, B. Kamaplath Humanized anti-CD20 monoclonal antibody (Rituximab) treatment for post-transplant lymphoproliferative disorder Clin Transplant 17 2003 417 422
13. N.D. Zilz, L.J. Olson, C.G. McGregor Treatment of post-transplant lymphoproliferative disorder with monoclonal CD20 antibody (rituximab) after heart transplantation J Heart Lung Transplant 20 2001 770 772
14. J. Herman, P. Vandenberghe, I. van den Heuvel Successful treatment with rituximab of lymphoproliferative disorder in a child after cardiac transplantation J Heart Lung Transplant 21 2002 1304 1309
15. N. Milpied, B. Vasseur, N. Parquet Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder a retrospective analysis on 32 patients Ann Oncol 11 suppl 1 2000 113 116
16. S. Skoda-Smith, V.K. Douglas, P. Mehta Treatment of post-transplant lymphoproliferative disease with induction chemotherapy followed by haploidentical peripheral blood stem cell transplantation and rituximab Bone Marrow Transplant 27 2001 329 332
17. H.E. Garrett, K. Groshart, D. Duvall-Seaman Treatment of humoral rejection with rituximab Ann Thorac Surg 74 2002 1240 1242
18. J.M. Aranda, J.C. Scornik, S.J. Normann Anti-CD20 monoclonal antibody (rituximab) therapy for acute cardiac humoral rejection a case report Transplantation 73 2002 907 910
19. E.H. Hammond, J.K. Hansen, L.S. Spencer Immunofluorescence of endomyocardial biopsy specimens methods and interpretation J Heart Transplant 12 suppl 1993 S113 S124
20. Y.T. Becker, B.N. Becker, J.D. Pirsch Rituximab as treatment for refractory kidney transplant rejection Am J Transplant 4 2004 996 1001
21. H. Hagberg, E. Holmbom Risk factors for side effects during first infusion of rituximab - definition of a low risk group Med Oncol 17; 2000 218 221
22. W.M. Book, L. Kelley, M.B. Gravanis Fulminant mixed humoral and cellular rejection in a cardiac transplant recipient a review of the histologic findings and literature J Heart Lung Transplant 22 2003 604 607